Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours

References

• Ely S. Personalized medicine: individualized care of cancer patients. Transl Res 2009;154:303–8.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007;177:75–9; discussion 9.
   PubMed Web of Science ®Google Scholar
• Andius P, Holmang S. Bacillus Calmette–Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004;93:980–4.
   PubMed Web of Science ®Google Scholar
• Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette–Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96–100; discussion 100.
   PubMed Web of Science ®Google Scholar
• Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF. Outcomes after intravesical bacillus Calmette–Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000;163:1120–3.
   PubMed Web of Science ®Google Scholar
• Soukup V, Babjuk M, Duskova J, Pesl M, Szakaczova M, Zamecnik L, et al. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in T1 urothelial urinary bladder carcinoma? Urol Int 2008;80:413–18.
   Google Scholar
• Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231–8; discussion 8.
   PubMed Web of Science ®Google Scholar
• Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O’Donnell MA, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 2009;103:475–9.
   PubMed Web of Science ®Google Scholar
• Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008;180:1928–32; discussion 32.
   PubMed Web of Science ®Google Scholar
• Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009;182:2625–30.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122:444–52.
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010;28:401–8.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008:154–65.
   Google Scholar
• Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463–72.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012;Mar27. [Epub ahead of print].
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5; discussion 75–7.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803–4.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48.
   PubMed Web of Science ®Google Scholar
• Reuter VE, Epstein JI, Amin MB, Mostofi FK. The “WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms”: continued discussion. Hum Pathol 1999;30:879–80.
   PubMed Web of Science ®Google Scholar
• Algaba F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol 2006;16:367–71.
   Google Scholar
• Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165:808–10.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378–84.
   PubMed Web of Science ®Google Scholar
• Lee MC, Levin HS, Jones JS. The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol 2010;183:921–7.
   PubMedGoogle Scholar